- TLDR Biotech
- Archive
- Page 3
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | October 1 - 2, 2025
🧬 Jazz Pharma + PharmaMar's Zepzelca approved for first-line maintenance treatment in extensive-stage small-cell lung cancer, Cartography's $67M Series B in pursuit of “differentiated” cancer drugs, Amgens touts "landmark" Ph3 win for PCSK9 inhibitor in cardiovascular event prevention, Pfizer + C4 Therapeutics sign clinical trial + supply agreement, Vaxcyte's up to $1B Thermo Fisher deal for fill-finish space access, Daiichi Sankyo opens third international R&D site (this one in San Diego)
Biotech & Pharma Updates | September 30 - October 1, 2025
🧬 Who's who of big pharma pools data in bid for better AI models, Halozyme expands subcutaneous delivery reach with up to $900M Elektrofi acquisition, AbbVie unveils $70M investment in Massachusetts bioresearch center, Ansa's $54.4M Series B to fuel DNA synthesis ambitions, Novartis nabs FDA approval first in oral BTK blocker for chronic spontaneous urticaria, Trump admins delays 100% tariff on branded pharmaceuticals
Biotech & Pharma Updates | September 29 - 30, 2025
🧬 Pfizer first to embrace MFN drug pricing + DTC via upcoming "TrumpRx" website, Merck & Co. published positive Winrevair Ph3 data in pulmonary arterial hypertension, Barinthus Therapeutics + Clywedog Therapeutics reverse merger, Rovi to acquire Phoenix-based BMS facility, AstraZeneca to "harmonize its share listing structure" via direct NYSE listing, EMA publishes draft guidance on including patient perspective in drug approval process
Biotech & Pharma Updates | September 28 - 29, 2025
🧬 Genmab ponies up $8B for Merus acquisition - eyes bispecific cancer assets, AstraZeneca + Daiichi Sankyo's Enhertu ADC beats Roche's Kadcyla in early breast cancer trial, Gilead in-licenses Health Hope Pharma's P-gp inhibitor in virology space for $10M upfront + $72.5M biobucks, FDA approves J&J's Tremfya in pediatric plaque psoriasis, Star Therapeutics lands $125M Series D for bleeding disorder aspirations, Full-Life Technologies $77M Series C + debt financing for radiopharma aspirations
Biotech & Pharma Updates | September 25 - 28, 2025
🧬 AstraZeneca joins direct-to-consumer fray with Oct 1 platform launch, Sanofi caps all insulin products in the US to $35/month (regardless of insurance), Amgen commits $650M to Puerto Rico site expansion, Eli Lilly opens biotech incubator in San Diego (able to fit up to 15 companies & 250 employees), Lotus buys-out Alvogen for up to $2B, Cure Alzheimer's Fund receives $50M gift to support research, FDA approves Regeneron's ANGPTL3 antibody to treat children 1 - 5 years of age with homozygous familial hypercholesterolemia
Biotech & Pharma Updates | September 24 - 25, 2025
🧬 FDA draft docs for faster CGT drug development, Eli Lilly lands a pair of approvals (FDA approval for oral SERD in breast cancer + EC approval for Kisunla in early symptomatic Alzheimer's), Merck & Co. in-licenses Evaxion's AI-platform based vaccine candidate for $7.5M upfront + $592M biobucks, NIH pledges $87M for organoid center in accelerating shift away from animal testing, UK may attempt big pharma damage control by "fix[ing] the commercial environment" (raising prescription drug prices)
Biotech & Pharma Updates | September 23 - 24, 2025
🧬 uniQure's Huntington's gene therapy slows down disease progression by 75% over 3 years in Ph2 trial, Glenmark signs up to $1B ADC deal with Hengrui Pharma, Roche presents new Ocrevus data with "significant benefit" in preventing MS-related disability progress, Moderna opens new UK vaccine manufacturing/R&D site amongst other big pharma exits, Fujifilm Biotechnologies opens doors to new $3.2B facility as one of the "largest cell culture biomanufacturing sites in the U.S.", Sparrow Pharmaceuticals lands $95M Series B to help T2D patients with elevated cortisol
Biotech & Pharma Updates | September 22 - 23, 2025
🧬 Eli Lilly drops $6.5B on Houston API plant, BMS' multiple myeloma protein degrader iberdomide hits a Ph3 goal, Merck & Co. commits further $349M into Variational AI drug discovery partnership, atai Life Sciences & Beckley Psytech report positive Ph2a data for DMT analog in treatment resistant depression, Sanofi commits further $625M into venture investment arm Sanofi Ventures, Manas AI touts $26M seed extension for "full-stack, AI native drug discovery and development"
Biotech & Pharma Updates | September 21 - 22, 2025
🧬 Pfizer's $4.9B obesity play with Metsera acquisition, Avenzo Tx's $60M Series B for "best-in-class oncology drug", Until's organ cryopreservation ambitions lead to $58M Series A, Roche posts Ph3 win for oral selective estrogen receptor degrader in breast cancer, Ionis' Alexander disease antisense oligonucleotide Phase 3 win, Trump admin continues baffling everyone - now linking Tylenol use in pregnancy to autism
Biotech & Pharma Updates | September 18 - 21, 2025
🧬 Merck & Co.'s Keytruda gets subcutaneous FDA ok, Novo Nordisk's once-weekly Type 2 diabetes combo-therapy lands CHMP nod, Merck KGaA opens €150m "climate-neutral" Cork Ireland facility, Eli Lilly plans orforglipron launch in India (citing no cold chain required versus weight-loss injectables), AusperBio lands $63M Series B2 towards chronic hep B functional cures, "bombardment of [Facebook] spam" lands Eli Lilly in UK marketing watchdog hot water
Biotech & Pharma Updates | September 17 - 18, 2025
🧬 Roche dives into MASH space with $2.4B 89bio buy, T.Rx Capital launches with $77.5M to bet on companies at the "intersection of technology & biology", MilliporeSigma opens €150M (+200 jobs) filtration plant in Ireland, Lexicon pushes non-opioid pain hopeful pilavapadin to Ph3 after post-hoc analysis, Fujifilm + argenx partner on US-based Vyvgart manufacturing, Carisma looks all but sunk as reverse-merger slips and BioNTech leaves partnership, bluebird bio rebrands as (old name) Genetix Biotherapeutics